Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares iBoxx $ High Yield Corporate Bond ETF (HYG) vs Medpace Holdings Inc (MEDP) Price & Performance

iShares iBoxx $ High Yield Corporate Bond ETFTrade
Medpace Holdings IncTrade

Price performance (Past 24H)

Key statistics

iShares iBoxx $ High Yield Corporate Bond ETF vs Medpace Holdings Inc — how do they compare? iShares iBoxx $ High Yield Corporate Bond ETF trades at $79.69, while Medpace Holdings Inc trades at $519.93 (market cap $15.08B). The key difference: Medpace Holdings Inc is trading nearer its 52-week high, iShares iBoxx $ High Yield Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.

HYGMEDP
Sector
Fixed IncomeTechnology
52-Week High
$81.32$620.59
52-Week Low
$78.72$308.88
Market Cap
$15.08B
Enterprise Value
$14.55B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares iBoxx $ High Yield Corporate Bond ETF

HYG trades at $79.68, up slightly by 0.04% today, but technical indicators signal a bearish trend with moving averages and overall signals pointing to selling pressure. The fund has declared dividends for 2026, including $0.37 and $0.41 payouts, amid a backdrop of high bond market volatility and investor caution. Recent news highlights elevated put volume and bearish bets against high-yield bonds, reflecting broader market uncertainty.

The outlook for HYG is cautious due to bearish technicals and macroeconomic headwinds like potential Fed rate hikes. Risks include interest rate sensitivity and inflation pressures, but the dividend yield may attract income-focused investors. Wall Street sentiment is mixed, with institutional flows into bond ETFs offering some support amid prevailing risks.

Medpace Holdings Inc

MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.

MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares iBoxx $ High Yield Corporate Bond ETF

HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.

Read more on HYG

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP